User:Tkadm30/Notebook/DHA: Difference between revisions
From OpenWetWare
< User:Tkadm30 | Notebook
| Line 13: | Line 13: | ||
* Ethanolamide metabolite of DHA. | * Ethanolamide metabolite of DHA. | ||
* Derivative of anandamide. | * Derivative of anandamide. | ||
* A | * A synaptogenic endocannabinoid with antiglutamatergic and neuroprotective effects that induce synaptogenesis in vivo. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930808/ PMC] | ||
=== See also === | === See also === | ||
* https://en.wikipedia.org/wiki/N-Acylethanolamine | * https://en.wikipedia.org/wiki/N-Acylethanolamine | ||
Revision as of 14:00, 28 August 2015
DHA (docosahexaenoic acid)
DHA supplementation may promote persistent synaptic plasticity in the hippocampus:
- DHA supplementation may enhance activity-dependent synaptic plasticity and cognition by regulating BDNF expression and glutamate release from hippocampal astrocytes. Furthermore, BDNF expression may requires adenosine A2A receptor activation to induce long-term potentiation (LTP). Thus, BDNF-induced synaptogenesis is enhanced by DHA supplementation to neurons, while DHEA may protect neurons from glutamate excitoxicity and inflammation.
DHA may increase CREB function by upregulation of mature BDNF (mBDNF) levels:
- mBDNF activate the TrkB receptor and decrease the excitability of GABAergic interneurons. PMID
- DHA-induced CREB phosphorylation enhance hippocampal plasticity and LTP through cAMP response element (CRE)-mediated gene induction and PPARs expression. PMC PMID
Neuroprotective properties of DHA:
- DHA is neuroprotective and controlled by the P2RX7 purinoreceptor. PMID
- DHA exert proneurogenic functions on activated microglia cells. PMID
DHEA (N-docosahexaenoyl ethanolamide)
- Ethanolamide metabolite of DHA.
- Derivative of anandamide.
- A synaptogenic endocannabinoid with antiglutamatergic and neuroprotective effects that induce synaptogenesis in vivo. PMC
